Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Klaus Jung

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Anatomy

Prostate

Physiology

Neoplastic Gene Expression Regulation

Procedures

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
113
Loening, Stefan
110
Lein, Michael
82
Schnorr, Dietmar
76
Stephan, Carsten
45
Kristiansen, Glen
33
Diamandis, Eleftherios
23
Brux, Brigitte
21
Sinha, Pranav
20
Cammann, Henning
18
Yousef, George
16
Dietel, Manfred
14
Deger, Serdar
13
Rudolph, Birgit
12
Meyer, Hellmuth-Alexander
12
Miller, Kurt

Sign-in to see all Coauthors

Publications

TOP 3
Stephan Carsten; Cammann Henning; Deger Serdar; Schrader Mark; Meyer Hellmuth A; Miller Kurt; Lein Michael; Jung Klaus
Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
Abramjuk Claudia; Bueschges Michael; Schnorr Jörg; Jung Klaus; Staack Andrea; Lein Michael
Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo.
Stephan Carsten; Rittenhouse Harry; Cammann Henning; Lein Michael; Schrader Mark; Deger Serdar; Miller Kurt; Jung Klaus
New markers and multivariate models for prostate cancer detection.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Klaus Jung (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Stephan Carsten; Cammann Henning; Deger Serdar; Schrader Mark; Meyer Hellmuth A; Miller Kurt; Lein Michael; Jung Klaus
Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
Urology 2009;74(4):873-7.
2009: Abramjuk Claudia; Bueschges Michael; Schnorr Jörg; Jung Klaus; Staack Andrea; Lein Michael
Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo.
Oncology reports 2009;22(2):409-14.
2009: Stephan Carsten; Rittenhouse Harry; Cammann Henning; Lein Michael; Schrader Mark; Deger Serdar; Miller Kurt; Jung Klaus
New markers and multivariate models for prostate cancer detection.
Anticancer research 2009;29(7):2589-600.
2009: Lein Michael; Miller Kurt; Wirth Manfred; Weissbach Lothar; May Christoph; Schmidt Katja; Haus Ulrike; Schrader Mark; Jung Klaus
Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid.
The Prostate 2009;69(6):624-32.
2009: Stephan Carsten; Bangma Chris; Vignati Giulio; Bartsch Georg; Lein Michael; Jung Klaus; Philippe Marianne; Semjonow Axel; Catalona William J
20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers.
The International journal of biological markers 2009;24(2):65-9.
2009: Gutwein Paul; Schramme Anja; Sinke Nina; Abdel-Bakky Mohamed Sadek; Voss Beren; Obermüller Nicholas; Doberstein Kai; Koziolek Michael; Fritzsche Florian; Johannsen Manfred; Jung Klaus; Schaider Helmut; Altevogt Peter; Ludwig Andreas; Pfeilschifter Josef; Kristiansen Glen
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
European journal of cancer (Oxford, England : 1990) 2009;45(3):478-89.
2009: Stephan Carsten; Kahrs Anna-Maria; Cammann Henning; Lein Michael; Schrader Mark; Deger Serdar; Miller Kurt; Jung Klaus
A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.
The Prostate 2009;69(2):198-207.
2009: Jung Klaus; Lein Michael
By mistakes we learn: determination of matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 in serum yields doubtful results.
Journal of clinical periodontology 2009;36(1):34-5; author reply 36-8.
2009: Jung Klaus; Mannello Ferdinando; Lein Michael
Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles.
Journal of translational medicine 2009;7():87.
2009: Stephan Carsten; Köpke Thomas; Semjonow Axel; Lein Michael; Deger Serdar; Schrader Mark; Miller Kurt; Jung Klaus
Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?
Clinical chemistry and laboratory medicine : CCLM / FESCC 2009;47(11):1325-31.
2009: Kempkensteffen Carsten; Fritzsche Florian Rudolf; Johannsen Manfred; Weikert Steffen; Hinz Stefan; Dietel Manfred; Riener Marc-Oliver; Moch Holger; Jung Klaus; Krause Hans; Miller Kurt; Kristiansen Glen
Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer.
BMC cancer 2009;9():276.
2009: Tölle Angelika; Jung Monika; Lein Michael; Johannsen Manfred; Miller Kurt; Moch Holger; Jung Klaus; Kristiansen Glen
Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
BMC cancer 2009;9():248.
2009: Schrader Mark; Kempkensteffen Carsten; Christoph Frank; Hinz Stefan; Weikert Steffen; Lein Michael; Krause Hans; Stephan Carsten; Jung Klaus; Hoepfner Michael; Albers Peter; Miller Kurt; Schostak Martin
Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options.
Oncology 2009;76(2):77-84.
2008: Jung Klaus
Measurement of matrix metalloproteinases and their tissue inhibitors in serum produces doubtful results.
The Journal of infectious diseases 2008;198(11):1722-3; author reply 1723-4.
2008: Mannello Ferdinando; Jung Klaus; Tonti Gaetana A; Canestrari Franco
Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood.
Clinical biochemistry 2008;41(18):1466-73.
2008: Jung Klaus
Words of wisdom. Re: the metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions.
European urology 2008;54(5):1198-9.
2008: Fritzsche Florian R; Oelrich Beibei; Johannsen Manfred; Kristiansen Ilka; Moch Holger; Jung Klaus; Kristiansen Glen
Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):7035-42.
2008: Jung Klaus; Ramankulov Azizbek; Schrader Mark; Miller Kurt; Lein Michael
Circulating matrix metalloproteinase-7: an early or metastatic marker for renal cell carcinoma?
Clinical chemistry 2008;54(11):1927-9.
2008: Fritzsche Florian R; Jung Monika; Tölle Angelika; Wild Peter; Hartmann Arndt; Wassermann Kirsten; Rabien Anja; Lein Michael; Dietel Manfred; Pilarsky Christian; Calvano Daniela; Grützmann Robert; Jung Klaus; Kristiansen Glen
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
European urology 2008;54(5):1097-106.
2008: Stephan Carsten; Jung Klaus; Lein Michael; Deger Serdar
Re: Al-Azab R, Toi A, Lockwood G, et al. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL (Urology 69:103-107, 2007).
Urology 2008;72(4):951.
2008: Kristiansen G; Fritzsche F R; Wassermann K; Jäger C; Tölls A; Lein M; Stephan C; Jung K; Pilarsky C; Dietel M; Moch H
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.
British journal of cancer 2008;99(6):939-48.
2008: Stephan Carsten; Cammann Henning; Meyer Hellmuth-Alexander; Müller Christian; Deger Serdar; Lein Michael; Jung Klaus
An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics.
BJU international 2008;102(7):799-805.
2008: Ramankulov Azizbek; Lein Michael; Johannsen Manfred; Schrader Mark; Miller Kurt; Loening Stefan A; Jung Klaus
Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.
Cancer letters 2008;269(1):85-92.
2008: Jung Klaus
A strong note of caution in using matrix metalloproteinase-1 and its inhibitor, TIMP-1 in serum as biomarkers in systolic heart failure.
Journal of internal medicine 2008;264(3):291-3.
2008: Mannello Ferdinando; Jung Klaus
Blood sampling affects circulating TIMP-1 concentration, a useful biomarker in estimating liver fibrosis stages.
Hepatology (Baltimore, Md.) 2008;48(2):688-9; author reply 689-90.
2008: Jung K
Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy.
British journal of cancer 2008;99(3):553-4; author reply 555.
2008: Fritzsche Florian Rudolf; Wassermann Kirsten; Rabien Anja; Schicktanz Hanka; Dankof Anja; Loening Stefan A; Dietel Manfred; Jung Klaus; Kristiansen Glen
CD146 protein in prostate cancer: revisited with two different antibodies.
Pathology 2008;40(5):457-64.
2008: Sardana Girish; Jung Klaus; Stephan Carsten; Diamandis Eleftherios P
Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Journal of proteome research 2008;7(8):3329-38.
2008: Stephan Carsten; Jung Klaus
Editorial comment on: diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter.
European urology 2008;54(2):369-70.
2008: Ramankulov Azizbek; Lein Michael; Johannsen Manfred; Schrader Mark; Miller Kurt; Jung Klaus
Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.
Cancer science 2008;99(6):1188-94.
2008: Jung Klaus
Serum samples are inappropriate for use in measuring circulating matrix metalloproteinases: comment on the article by Young-Min et al.
Arthritis and rheumatism 2008;58(5):1557-8; author reply 1559.
2008: Stephan Carsten; Cammann Henning; Lein Michael; Miller Kurt; Jung Klaus
Re: Application of artificial intelligence to the management of urological cancer. M. F. Abbod, J. W. Catto, D. A. Linkens and F. C. Hamdy J Urol 2007; 178: 1150-1156.
The Journal of urology 2008;179(5):2067.
2008: Jung Klaus
Matrix metalloproteinases do not properly work as peripheral blood biomarkers without taking into account the preanalytical impact of blood sampling.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2008;33(5):944; author reply 945.
2008: Jung Klaus; Klotzek Silke; Stephan Carsten; Mannello Ferdinando; Lein Michael
Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9.
Clinical chemistry 2008;54(4):772-3.
2008: Jung Klaus
Blood sampling and the measurement of circulating matrix metalloproteinase-8.
Clinica chimica acta; international journal of clinical chemistry 2008;390(1-2):156-7, author reply 158.
2008: Fritzsche F R; Oelrich B; Dietel M; Jung K; Kristiansen G
European and US publications in the 50 highest ranking pathology journals from 2000 to 2006.
Journal of clinical pathology 2008;61(4):474-81.
2008: Jung Klaus
Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(3):e15-6; author reply e17.
2008: Weichert W; Röske A; Gekeler V; Beckers T; Stephan C; Jung K; Fritzsche F R; Niesporek S; Denkert C; Dietel M; Kristiansen G
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.
British journal of cancer 2008;98(3):604-10.
2008: Niesporek Silvia; Kristiansen Glen; Thoma Andrea; Weichert Wilko; Noske Aurelia; Buckendahl Ann-Christin; Jung Klaus; Stephan Carsten; Dietel Manfred; Denkert Carsten
Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression.
International journal of oncology 2008;32(2):341-7.
2008: Fritzsche Florian R; Weichert Wilko; Röske Annika; Gekeler Volker; Beckers Thomas; Stephan Carsten; Jung Klaus; Scholman Katharina; Denkert Carsten; Dietel Manfred; Kristiansen Glen
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.
BMC cancer 2008;8():381.
2008: Fritzsche Florian Rudolf; Riener Mark-Oliver; Dietel Manfred; Moch Holger; Jung Klaus; Kristiansen Glen
GOLPH2 expression in renal cell cancer.
BMC urology 2008;8():15.
2008: Stephan Carsten; Kahrs Anna-Maria; Klotzek Silke; Reiche Janett; Müller Christian; Lein Michael; Deger Serdar; Miller Kurt; Jung Klaus
Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(5):623-9.
2008: Stephan Carsten; Büker Nicola; Cammann Henning; Meyer Hellmuth-Alexander; Lein Michael; Jung Klaus
Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity.
BMC urology 2008;8():10.
2008: Fritzsche Florian R; Wassermann Kirsten; Jung Monika; Tölle Angelika; Kristiansen Ilka; Lein Michael; Johannsen Manfred; Dietel Manfred; Jung Klaus; Kristiansen Glen
ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression.
BMC cancer 2008;8():179.
2008: Rabien Anja; Fritzsche Florian; Jung Monika; Diamandis Eleftherios P; Loening Stefan A; Dietel Manfred; Jung Klaus; Stephan Carsten; Kristiansen Glen
High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2008;29(1):1-8.
2007: Lein Michael; Wirth Manfred; Miller Kurt; Eickenberg Hans-Udo; Weissbach Lothar; Schmidt Katja; Haus Ulrike; Stephan Carsten; Meissner Sven; Loening Stefan A; Jung Klaus
Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
European urology 2007;52(5):1381-7.
2007: Oelrich Beibei; Peters Robert; Jung Klaus
A bibliometric evaluation of publications in urological journals among European Union countries between 2000-2005.
European urology 2007;52(4):1238-48.
2007: Stephan Carsten; Jung Klaus; Lein Michael; Diamandis Eleftherios P
PSA and other tissue kallikreins for prostate cancer detection.
European journal of cancer (Oxford, England : 1990) 2007;43(13):1918-26.
2007: Stephan Carsten; Xu Chuanliang; Finne Patrik; Cammann Henning; Meyer Hellmuth-Alexander; Lein Michael; Jung Klaus; Stenman Ulf-Hakan
Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations.
Urology 2007;70(3):596-601.
2007: Stephan C; Jung K; Cammann H; Kramer J; Kristiansen G; Loening S A; Lein M
[New serum markers in prostate carcinoma and their application to artificial neural networks]
Der Urologe. Ausg. A 2007;46(9):1084-6.
2007: Rabien A; Jung M; Fritzsche F; Loening S A; Kristiansen G; Jung K
[Tumor suppressor RECK in prostate carcinoma. Decreased RECK expression as indicator of proteolytic imbalance]
Der Urologe. Ausg. A 2007;46(9):1081-2.
2007: Jung M; Ohl F; Stephan C; Rabien A; Kristiansen G; Radonic A; Loening S A; Jung K
[Quantifying gene expression in prostate carcinoma. Which endogenous reference genes are suitable?]
Der Urologe. Ausg. A 2007;46(9):1083-4.
2007: Lein M; Ramankulov A; Stephan C; Kramer J; Loening S A; Jung K
[New serum markers of bone metastasis in prostate carcinoma]
Der Urologe. Ausg. A 2007;46(9):1087-8.
2007: Ludwig Stefan; Stephan Carsten; Lein Michael; Loening Stefan A; Jung Klaus
S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk-A re-evaluation study.
The Prostate 2007;67(12):1301-7.
2007: Rabien A; Kristiansen G; Diamandis E P; Jung K; Stephan C
[Human kallikreins as tumor markers. Validation of potential marker of prostate cancer in serum and tissue]
Der Urologe. Ausg. A 2007;46(9):1070-1.
2007: Ramankulov Azizbek; Lein Michael; Kristiansen Glen; Meyer Hellmuth-A; Loening Stefan A; Jung Klaus
Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma.
Journal of cancer research and clinical oncology 2007;133(9):643-52.
2007: Stephan Carsten; Meyer Hellmuth-Alexander; Paul Eva-Maria; Kristiansen Glen; Loening Stefan A; Lein Michael; Jung Klaus
Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
Anticancer research 2007;27(4A):1833-6.
2007: Stephan Carsten; Kramer Jürgen; Meyer Hellmuth-Alexander; Kristiansen Glen; Ziemer Sabine; Deger Serdar; Lein Michael; Loening Stefan A; Jung Klaus
Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
BJU international 2007;99(6):1427-31.
2007: Johannsen M; Gneveckow U; Taymoorian K; Thiesen B; Waldöfner N; Scholz R; Jung K; Jordan A; Wust P; Loening S A
Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2007;23(3):315-23.
2007: Cottrell Susan; Jung Klaus; Kristiansen Glen; Eltze Elke; Semjonow Axel; Ittmann Michael; Hartmann Arndt; Stamey Thomas; Haefliger Carolina; Weiss Gunter
Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
The Journal of urology 2007;177(5):1753-8.
2007: Stephan Carsten; Meyer Hellmuth-A; Cammann Henning; Lein Michael; Loening Stefan A; Jung Klaus
Re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 2007;51:1236-43.
European urology 2007;51(5):1446-7; author reply 1448.
2007: Rabien Anja; Burkhardt Mick; Jung Monika; Fritzsche Florian; Ringsdorf Martin; Schicktanz Hanka; Loening Stefan A; Kristiansen Glen; Jung Klaus
Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
European urology 2007;51(5):1259-66.
2007: Jung Klaus
Preanalytical biases in measurement of matrix metalloproteinases and their tissue inhibitors in peripheral blood.
The Journal of rheumatology 2007;34(4):890-2; author reply 892.
2007: Stephan Carsten; Cammann Henning; Meyer Hellmuth-A; Lein Michael; Jung Klaus
PSA and new biomarkers within multivariate models to improve early detection of prostate cancer.
Cancer letters 2007;249(1):18-29.
2007: Jung Klaus
Re: A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
European urology 2007;51(3):851-2.
2007: Stephan Carsten; Xu Chuanliang; Cammann Henning; Graefen Markus; Haese Alexander; Huland Hartwig; Semjonow Axel; Diamandis Eleftherios P; Remzi Mesut; Djavan Bob; Wildhagen Mark F; Blijenberg Bert G; Finne Patrik; Stenman Ulf-Hakan; Jung Klaus; Meyer Hellmuth-Alexander
Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men.
World journal of urology 2007;25(1):95-103.
2007: Tabarés Glòria; Jung Klaus; Reiche Janett; Stephan Carsten; Lein Michael; Peracaula Rosa; de Llorens Rafael; Hoesel Wolfgang
Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples.
Clinical biochemistry 2007;40(5-6):343-50.
2007: Denkert Carsten; Thoma Andrea; Niesporek Silvia; Weichert Wilko; Koch Ines; Noske Aurelia; Schicktanz Hanka; Burkhardt Mick; Jung Klaus; Dietel Manfred; Kristiansen Glen
Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.
The Prostate 2007;67(4):361-9.
2007: Jung Klaus; Hoesel Wolfgang; Reiche Jeanett; Deger Serdar; Kramer Jürgen; Loening Stefan A; Lein Michael; Stephan Carsten
Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
Urology 2007;69(2):320-5.
2007: Ramankulov Azizbek; Lein Michael; Kristiansen Glen; Loening Stefan A; Jung Klaus
Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer.
The Prostate 2007;67(3):330-40.
2007: Abramjuk Claudia; Lein Michael; Rothaug Winfried; Krell Hans-Willi; Loening Stefan A; Jung Klaus
Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
Cancer chemotherapy and pharmacology 2007;59(2):275-82.
2007: Gerlach Raquel F; Demacq Caroline; Jung Klaus; Tanus-Santos Jose E
Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.
Clinical biochemistry 2007;40(1-2):119-23.
2007: Jung Monika; Ramankulov Azizbek; Roigas Jan; Johannsen Manfred; Ringsdorf Martin; Kristiansen Glen; Jung Klaus
In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR.
BMC molecular biology 2007;8():47.
2006: Fritzsche Florian R; Jung Monika; Xu Chuanliang; Rabien Anja; Schicktanz Hanka; Stephan Carsten; Dietel Manfred; Jung Klaus; Kristiansen Glen
ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis.
Virchows Archiv : an international journal of pathology 2006;449(6):628-36.
2006: Lein Michael; Stibane Inna; Mansour Ramin; Hege Claudia; Roigas Jan; Wille Andreas; Jung Klaus; Kristiansen Glen; Schnorr Dietmar; Loening Stefan A; Deger Serdar
Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte.
European urology 2006;50(6):1278-82; discussion 1283-4.
2006: Stephan Carsten; Meyer Hellmuth-Alexander; Kwiatkowski Maciej; Recker Franz; Cammann Henning; Loening Stefan A; Jung Klaus; Lein Michael
A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
European urology 2006;50(5):1014-20.
2006: Jung Klaus; Gerlach Raquel F; Tanus-Santos Jose E
Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases.
Clinica chimica acta; international journal of clinical chemistry 2006;373(1-2):180-1; author reply 182.
2006: Jung Klaus; Lein Michael; Ringsdorf Martin; Roigas Jan; Schnorr Dietmar; Loening Stefan A; Staack Andrea
Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
The Journal of urology 2006;176(4 Pt 1):1326-31.
2006: Stephan Carsten; Meyer Hellmuth-Alexander; Cammann Henning; Nakamura Terukazu; Diamandis Eleftherios P; Jung Klaus
Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network.
Biological chemistry 2006;387(6):801-5.
2006: Ohl Falk; Jung Monika; Radonic Aleksandar; Sachs Markus; Loening Stefan A; Jung Klaus
Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer.
The Journal of urology 2006;175(5):1915-20.
2006: Bhuvarahamurthy Venugopal; Kristiansen Glen O; Johannsen Manfred; Loening Stefan A; Schnorr Dietmar; Jung Klaus; Staack Andrea
In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Oncology reports 2006;15(5):1379-84.
2006: Stephan Carsten; Xu Chuanliang; Brown David A; Breit Samuel N; Michael Anja; Nakamura Terukazu; Diamandis Eleftherios P; Meyer Hellmuth; Cammann Henning; Jung Klaus
Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network.
The Prostate 2006;66(6):651-9.
2006: Jung Klaus
Impact of blood sampling on circulating tissue inhibitors of metalloproteinases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(8):2648; author reply 2648-9.
2006: Jung Klaus; Lein Michael; Butz Hermann; Stephan Carsten; Loening Stefan A; Keller Thomas
New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics.
The Journal of urology 2006;175(4):1275-80.
2006: Sturm I; Stephan C; Gillissen B; Siebert R; Janz M; Radetzki S; Jung K; Loening S; Dörken B; Daniel P T
Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma.
Cell death and differentiation 2006;13(4):619-27.
2006: Stephan Carsten; Jung Klaus; Nakamura Terukazu; Yousef George M; Kristiansen Glen; Diamandis Eleftherios P
Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
International journal of urology : official journal of the Japanese Urological Association 2006;13(3):238-43.
2006: Fritzsche F; Gansukh T; Borgoño C A; Burkhardt M; Pahl S; Mayordomo E; Winzer K-J; Weichert W; Denkert C; Jung K; Stephan C; Dietel M; Diamandis E P; Dahl E; Kristiansen G
Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status.
British journal of cancer 2006;94(4):540-7.
2006: Brown David A; Stephan Carsten; Ward Robyn L; Law Mathew; Hunter Mark; Bauskin Asne R; Amin Janaki; Jung Klaus; Diamandis Eleftherios P; Hampton Garret M; Russell Pamela J; Giles Graham G; Breit Samuel N
Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(1):89-96.
2006: Stephan Carsten; Klaas Moritz; Müller Christian; Schnorr Dietmar; Loening Stefan A; Jung Klaus
Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.
Clinical chemistry 2006;52(1):59-64.
2006: Johannsen Manfred; Thiesen Burghard; Gneveckow Uwe; Taymoorian Kasra; Waldöfner Norbert; Scholz Regina; Deger Serdar; Jung Klaus; Loening Stefan A; Jordan Andreas
Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer.
The Prostate 2006;66(1):97-104.
2006: Staack Andrea; Badendieck Steffen; Schnorr Dietmar; Loening Stefan A; Jung Klaus
Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
BMC urology 2006;6():19.
2006: Jung Klaus
Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2006;44(4):500-2.
2005: Lein Michael; Semjonow Axel; Graefen Markus; Kwiatkowski Maciej; Abramjuk Claudia; Stephan Carsten; Haese Alexander; Chun Felix; Schnorr Dietmar; Loening Stefan A; Jung Klaus
A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
The Journal of urology 2005;174(6):2150-3.
2005: Stephan Carsten; Schnorr Dietmar; Loening Stefan A; Jung Klaus
Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
European urology 2005;48(6):1059-60; author reply 1060-1.
2005: Ohl Falk; Jung Monika; Xu Chuanliang; Stephan Carsten; Rabien Anja; Burkhardt Mick; Nitsche Andreas; Kristiansen Glen; Loening Stefan A; Radonic Aleksandar; Jung Klaus
Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?
Journal of molecular medicine (Berlin, Germany) 2005;83(12):1014-24.
2005: Jung Klaus; Meisser Arielle; Bischof Paul
Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes.
International journal of cancer. Journal international du cancer 2005;116(6):1000-1; author reply 1002-3.
2005: Stephan Carsten; Jung Klaus; Soosaipillai Antoninus; Yousef George M; Cammann Henning; Meyer Hellmuth; Xu Chuanliang; Diamandis Eleftherios P
Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
BJU international 2005;96(4):521-7.
2005: Abramjuk Claudia; Jung Klaus; Krell Hans-Willi; Juchem Rolf; Peters Robert; Taymoorian Kasra; Staack Andrea; Stephan Carsten; Schnorr Joerg; Loening Stefan A; Lein Michael
Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats.
Anti-cancer drugs 2005;16(8):855-61.
2005: Bhuvarahamurthy Venugopal; Schroeder Joerg; Kristiansen Glen; Roigas Jan; Denkert Carsten; Johannsen Manfred; Lein Michael; Loening Stefan A; Schnorr Dietmar; Jung Klaus; Staack Andrea
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Oncology reports 2005;14(3):777-82.
2005: Stephan Carsten; Stroebel Greta; Heinau Marc; Lenz Andre; Roemer Andreas; Lein Michael; Schnorr Dietmar; Loening Stefan A; Jung Klaus
The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Cancer 2005;104(5):993-1003.
2005: John M; Jung K
Pre-analytical conditions for the assessment of circulating MMP-9 and TIMP-1: consideration of pitfalls.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2005;26(2):364-5; author reply 365-6.
2005: Johannsen Manfred; Thiesen Burghard; Jordan Andreas; Taymoorian Kasra; Gneveckow Uwe; Waldöfner Norbert; Scholz Regina; Koch Martin; Lein Michael; Jung Klaus; Loening Stefan A
Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model.
The Prostate 2005;64(3):283-92.
2005: John Matthias; Jung Klaus
Consideration of important preanalytical conditions for the assessment of circulating matrix metalloproteinase-9.
American journal of respiratory and critical care medicine 2005;172(2):254; author reply 254.
2005: Stephan Carsten; Cammann Henning; Jung Klaus
Artificial neural networks: has the time come for their use in prostate cancer patients?
Nature clinical practice. Urology 2005;2(6):262-3.
2005: Geheeb Martina; Rabien Anja; Ohl Falk; Jung Monika; Jung Klaus
Misinterpretation of quantitative RT-PCR results: A comment on the article by Ohashi et al. "RNA degradation in human breast tissue after surgical removal: a time course study", Exp. Mol. Pathol. 77 (2004) 98-103.
Experimental and molecular pathology 2005;78(3):263; author reply 264.
2005: Jung Klaus
Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors?
Journal of neuroimmunology 2005;162(1-2):1-2.
2005: Jung Klaus
Consideration of preanalytical conditions to use circulating matrix metalloproteinases as diagnostic markers.
Transplantation 2005;79(6):744.
2005: Keller Thomas; Butz Hermann; Lein Michael; Kwiatkowski Maciej; Semjonow Axel; Luboldt Hans-Joachim; Hammerer Peter; Stephan Carsten; Jung Klaus
Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen.
Clinical chemistry 2005;51(3):532-9.
2005: Michael Iacovos P; Kurlender Lisa; Memari Nader; Yousef George M; Du Daisy; Grass Linda; Stephan Carsten; Jung Klaus; Diamandis Eleftherios P
Intron retention: a common splicing event within the human kallikrein gene family.
Clinical chemistry 2005;51(3):506-15.
2005: Jung Klaus
Careful attention to blood sampling as a preanalytical determinant of circulating matrix metalloproteinase 9 to avoid misinterpretations: comment on the article by Ainiala et al.
Arthritis and rheumatism 2005;52(2):673-4; author reply 674.
2005: Xu Chuanliang; Jung Monika; Burkhardt Mick; Stephan Carsten; Schnorr Dietmar; Loening Stefan; Jung Klaus; Dietel Manfred; Kristiansen Glen
Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.
The Prostate 2005;62(3):224-32.
2005: Michael Anja; Stephan Carsten; Kristiansen Glen; Burckhardt Mick; Loening Stefan A; Schnorr Dietmar; Jung Klaus
Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
The Prostate 2005;62(1):34-9.
2004: Roemer Andreas; Schwettmann Lutz; Jung Monika; Stephan Carsten; Roigas Jan; Kristiansen Glen; Loening Stefan A; Lichtinghagen Ralf; Jung Klaus
The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?
The Journal of urology 2004;172(6 Pt 1):2162-6.
2004: Jung Klaus; Reiche Janett; Boehme Axel; Stephan Carsten; Loening Stephan A; Schnorr Dietmar; Hoesel Wolfgang; Sinha Pranav
Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer.
Clinical chemistry 2004;50(12):2292-301.
2004: Bhuvarahamurthy Venugopal; Schroeder Joerg; Denkert Carsten; Kristiansen Glen; Schnorr Dietmar; Loening Stefan A; Jung Klaus; Staack Andrea
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Oncology reports 2004;12(4):909-13.
2004: Yousef George M; White Nicole M A; Kurlender Lisa; Michael Iacovos; Memari Nader; Robb John-Desmond; Katsaros Dionyssios; Stephan Carsten; Jung Klaus; Diamandis Eleftherios P
The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2004;25(5-6):221-7.
2004: Jung Klaus; Lein Michael; Stephan Carsten; Von Hösslin Katharina; Semjonow Axel; Sinha Pranav; Loening Stefan A; Schnorr Dietmar
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
International journal of cancer. Journal international du cancer 2004;111(5):783-91.
2004: Weichert Wilko; Schmidt Mathias; Gekeler Volker; Denkert Carsten; Stephan Carsten; Jung Klaus; Loening Stefan; Dietel Manfred; Kristiansen Glen
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades.
The Prostate 2004;60(3):240-5.
2004: Johannsen Manfred; Jordan Andreas; Scholz Regina; Koch Martin; Lein Michael; Deger Serdar; Roigas Jan; Jung Klaus; Loening Stefan
Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer.
Journal of endourology / Endourological Society 2004;18(5):495-500.
2004: Staack Andrea; Tolic Diana; Kristiansen Glen; Schnorr Dietmar; Loening Stefan A; Jung Klaus
Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder.
Urology 2004;63(6):1089-94.
2004: Stephan C; Lein M; Schnorr D; Loening S A; Jung K
Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy.
BJU international 2004;93(9):1360-1.
2004: Kurlender Lisa; Yousef George M; Memari Nader; Robb John-Desmond; Michael Iacovos P; Borgoño Carla; Katsaros Dionyssios; Stephan Carsten; Jung Klaus; Diamandis Eleftherios P
Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2004;25(3):149-56.
2004: Yousef George M; Borgoño Carla A; Michael Iacovos P; Davidian Christine; Stephan Carsten; Jung Klaus; Diamandis Eleftherios P
Molecular cloning of a new gene which is differentially expressed in breast and prostate cancers.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2004;25(3):122-33.
2004: Stephan Carsten; Jung Klaus; Cammann Henning
Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate-specific antigen levels < or = 10 ng/ml.
Cancer 2004;100(9):1989-90; author reply 1989-90.
2004: Jung Klaus; Stephan Carsten; Lewandowski Michaela; Klotzek Silke; Jung Monika; Kristiansen Glen; Lein Michael; Loening Stefan A; Schnorr Dietmar
Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer.
Cancer letters 2004;205(2):173-80.
2004: Michael Anja; Stephan Carsten; Schnorr Dietmar; Loening Stephan A; Jung Klaus
Serum macrophage migration inhibitory factor is not elevated in patients with prostate cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004;13(2):328-9.
2004: Roemer Andreas; Schwettmann Lutz; Jung Monika; Roigas Jan; Kristiansen Glen; Schnorr Dietmar; Loening Stefan A; Jung Klaus; Lichtinghagen Ralf
Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome.
Oncology reports 2004;11(2):529-36.
2004: Kristiansen Glen; Pilarsky Christian; Pervan Janja; Stürzebecher Burkhard; Stephan Carsten; Jung Klaus; Loening Stefan; Rosenthal Andre; Dietel Manfred
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.
The Prostate 2004;58(2):183-92.
2004: Stephan Carsten; Yousef George M; Scorilas Andreas; Jung Klaus; Jung Monika; Kristiansen Glen; Hauptmann Steffen; Kishi Tadaaki; Nakamura Terukazu; Loening Stefan A; Diamandis Eleftherios P
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
The Journal of urology 2004;171(1):187-91.
2003: Jung Klaus; Stephan Carsten; Semjonow Axel; Lein Michael; Schnorr Dietmar; Loening Stefan A
Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
The Journal of urology 2003;170(6 Pt 1):2302-5.
2003: Roigas J; Deger S; Schroeder J; Wille A; Turk I; Brux B; Jung K; Schnorr D; Loening S A
Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma.
Urological research 2003;31(6):358-62.
2003: Nakamura Terukazu; Scorilas Andreas; Stephan Carsten; Jung Klaus; Soosaipillai Antoninus R; Diamandis Eleftherios P
The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia.
Cancer research 2003;63(19):6543-6.
2003: Lein Michael; Kwiatkowski Maciej; Semjonow Axel; Luboldt Hans-Joachim; Hammerer Peter; Stephan Carsten; Klevecka Virgilijus; Taymoorian Kasra; Schnorr Dietmar; Recker Franz; Loening Stefan A; Jung Klaus
A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations.
The Journal of urology 2003;170(4 Pt 1):1175-9.
2003: Stephan C; Vogel B; Cammann H; Lein M; Klevecka V; Sinha P; Kristiansen G; Schnorr D; Jung K; Loening S A
[An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l]
Der Urologe. Ausg. A 2003;42(9):1221-9.
2003: Yousef George M; Stephan Carsten; Scorilas Andreas; Ellatif Mohamed Abd; Jung Klaus; Kristiansen Glen; Jung Monika; Polymeris Mary-Ellen; Diamandis Eleftherios P
Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues.
The Prostate 2003;56(4):287-92.
2003: Jung Monika; Klotzek Silke; Lewandowski Michaela; Fleischhacker Michael; Jung Klaus
Changes in concentration of DNA in serum and plasma during storage of blood samples.
Clinical chemistry 2003;49(6 Pt 1):1028-9.
2003: Wesseling Sebastian; Stephan Carsten; Semjonow Axel; Lein Michael; Brux Brigitte; Sinha Pranav; Loening Stefan A; Jung Klaus
Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
Clinical chemistry 2003;49(6 Pt 1):887-94.
2003: Lichtinghagen Ralf; Musholt Petra B; Stephan Carsten; Lein Michael; Kristiansen Glen; Hauptmann Steffen; Rudolph Birgit; Schnorr Dietmar; Loening Stefan A; Jung Klaus
mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue.
Anticancer research 2003;23(3B):2617-24.
2003: Nakamura Terukazu; Stephan Carsten; Scorilas Andreas; Yousef George M; Jung Klaus; Diamandis Eleftherios P
Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues.
Urology 2003;61(5):1042-6.
2003: Jung Monika; Römer Andreas; Keyszer Gernot; Lein Michael; Kristiansen Glen; Schnorr Dietmar; Loening Stefan A; Jung Klaus
mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue.
The Prostate 2003;55(2):89-98.
2003: Nakamura T; Scorilas A; Stephan C; Yousef G M; Kristiansen G; Jung K; Diamandis E P
Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues.
British journal of cancer 2003;88(7):1101-4.
2003: Stephan Carsten; Wesseling Sebastian; Schink Tania; Jung Klaus
Comparison of eight computer programs for receiver-operating characteristic analysis.
Clinical chemistry 2003;49(3):433-9.
2003: Jung Klaus; Krell Hans-Willi; Ortel Bernhard; Hasan Tayyaba; Römer Andreas; Schnorr Dietmar; Loening Stefan A; Lein Michael
Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats.
The Prostate 2003;54(3):206-11.
2003: Stephan Carsten; Yousef George M; Scorilas Andreas; Jung Klaus; Jung Monika; Kristiansen Glen; Hauptmann Steffen; Bharaj Bhupinder S; Nakamura Terukazu; Loening Stefan A; Diamandis Eleftherios P
Quantitative analysis of kallikrein 15 gene expression in prostate tissue.
The Journal of urology 2003;169(1):361-4.
2002: Baumgart E; Lenk S V; Loening S A; Jung K
Tissue inhibitors of metalloproteinases 1 and 2 in human seminal plasma and their association with spermatozoa.
International journal of andrology 2002;25(6):369-71.
2002: Baumgart E; Lenk S V; Loening S A; Jung K
Quantitative differences in matrix metalloproteinase (MMP)-2, but not in MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 or TIMP-2, in seminal plasma of normozoospermic and azoospermic patients.
Human reproduction (Oxford, England) 2002;17(11):2919-23.
2002: Yousef George M; Obiezu Christina V; Jung Klaus; Stephan Carsten; Scorilas Andreas; Diamandis Eleftherios P
Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues.
Urology 2002;60(4):714-8.
2002: Lichtinghagen Ralf; Musholt Petra B; Lein Michael; Römer Andreas; Rudolph Birgit; Kristiansen Glen; Hauptmann Steffen; Schnorr Dietmar; Loening Stefan A; Jung Klaus
Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue.
European urology 2002;42(4):398-406.
2002: Jung Klaus; Lein Michael; Roemer Ardreas; Lichtinghagen Ralf
Circulating gelatinase B (MMP-9)--the impact of the preanalytical step of blood collection.
Matrix biology : journal of the International Society for Matrix Biology 2002;21(5):381-2.
2002: Stephan Carsten; Cammann Henning; Semjonow Axel; Diamandis Eleftherios P; Wymenga Leon F A; Lein Michael; Sinha Pranav; Loening Stefan A; Jung Klaus
Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies.
Clinical chemistry 2002;48(8):1279-87.
2002: Obiezu Christina V; Soosaipillai Antoninus; Jung Klaus; Stephan Carsten; Scorilas Andreas; Howarth David H C; Diamandis Eleftherios P
Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry.
Clinical chemistry 2002;48(8):1232-40.
2002: Jung K; Lein M; Hösslin K v; Grosse A; Roth S; Possinger K; Lüftner D
Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults.
The International journal of biological markers 2002;17(3):177-81.
2002: Mangoldt D; Sinn B; Lein M; Krell H W; Schnorr D; Loening S A; Jung K
The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells.
Apoptosis : an international journal on programmed cell death 2002;7(3):217-20.
2002: Stephan Carsten; Jung Klaus; Cammann Henning; Vogel Birgit; Brux Brigitte; Kristiansen Glen; Rudolph Birgit; Hauptmann Steffen; Lein Michael; Schnorr Dietmar; Sinha Pranav; Loening Stefan A
An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: results of a 5-year investigation.
International journal of cancer. Journal international du cancer 2002;99(3):466-73.
2002: Filler Guido; Priem Friedrich; Lepage Nathalie; Sinha Pranav; Vollmer Ilka; Clark Heather; Keely Erin; Matzinger Mary; Akbari Ayub; Althaus Harald; Jung Klaus
Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children.
Clinical chemistry 2002;48(5):729-36.
2002: Yousef George M; Scorilas Andreas; Chang Albert; Rendl Laura; Diamandis Maria; Jung Klaus; Diamandis Eleftherios P
Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues.
The Prostate 2002;51(2):126-32.
2002: Bharaj Bhupinder B; Luo Liu-Ying; Jung Klaus; Stephan Carsten; Diamandis Eleftherios P
Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers.
The Prostate 2002;51(1):35-41.
2002: Lein Michael; Jung Klaus; Ortel Bernhard; Stephan Carsten; Rothaug Winfried; Juchem Rolf; Johannsen Manfred; Deger Serdar; Schnorr Dietmar; Loening Stefan; Krell Hans-Willi
The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model.
Oncogene 2002;21(13):2089-96.
2002: John M; Oltmanns U; Witt C; Jung K
Re: Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer (Respir Med 2001; 95: 1-4).
Respiratory medicine 2002;96(2):126-9.
2002: Staack Andrea; Koenig Frank; Daniltchenko Dmitri; Hauptmann Steffen; Loening Stefan A; Schnorr Dietmar; Jung Klaus
Cathepsins B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder.
Urology 2002;59(2):308-12.
2002: Stephan Carsten; Jung Klaus; Diamandis Eleftherios P; Rittenhouse Harry G; Lein Michael; Loening Stefan A
Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer.
Urology 2002;59(1):2-8.
2002: John Matthias; Oltmanns Ute; Fietze Ingo; Witt Christian; Jung Klaus
Increased production of matrix metalloproteinase-2 in alveolar macrophages and regulation by interleukin-10 in patients with acute pulmonary sarcoidosis.
Experimental lung research 2002;28(1):55-68.
2002: Zhang Ju; Jung Klaus; Lein Michael; Kristiansen Glen; Rudolph Birgit; Hauptmann Steffen; Schnorr Dietmar; Loening Stefan A; Lichtinghagen Ralf
Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines.
The Prostate 2002;50(1):38-45.
2002: Stephan C; Jung K; Schnorr D; Lein M; Sinha P; Loening S A
Re: a prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. I.D.C. Mitchell, B.L. Croal, A. Dickie, N.P. Cohen and I. Ross. J Urol, 165: 1549-1553, 2001.
The Journal of urology 2002;167(1):259-60.
2001: Priem F; Althaus H; Jung K; Sinha P
Beta-trace protein is not better than cystatin C as an indicator of reduced glomerular filtration rate.
Clinical chemistry 2001;47(12):2181.
2001: Jung K; Lein M; Laube C; Lichtinghagen R
Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood.
Clinica chimica acta; international journal of clinical chemistry 2001;314(1-2):241-4.
2001: Jung K; Lein M; von Hösslin K; Brux B; Schnorr D; Loening S A; Sinha P
Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer.
Clinical chemistry 2001;47(11):2061-3.
2001: Chang A; Yousef G M; Jung K; Rajpert-De Meyts E; Diamandis E P
Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: differential expression in the human testis and testicular cancer.
Anticancer research 2001;21(5):3147-52.
2001: Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening S A
Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2001;22(5):282-5.
2001: Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening S A; Sinha P
Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
International journal of cancer. Journal international du cancer 2001;93(5):759-65.
2001: Sidiropoulos M; Chang A; Jung K; Diamandis E P
Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer.
British journal of cancer 2001;85(3):393-7.
2001: Luo L Y; Rajpert-De Meyts E R; Jung K; Diamandis E P
Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue.
British journal of cancer 2001;85(2):220-4.
2001: Scorilas A; Yousef G M; Jung K; Rajpert-De Meyts E; Carsten S; Diamandis E P
Identification and characterization of a novel human testis-specific kinase substrate gene which is downregulated in testicular tumors.
Biochemical and biophysical research communications 2001;285(2):400-8.
2001: Yousef G M; Diamandis M; Jung K; Diamandis E P
Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis.
Genomics 2001;74(3):385-95.
2001: Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt H J; Brux B; Stephan C; Schnorr D; Loening S A
A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
The Prostate 2001;47(2):77-84.
2001: Yousef G M; Magklara A; Chang A; Jung K; Katsaros D; Diamandis E P
Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies.
Cancer research 2001;61(8):3425-31.
2001: Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening S A
Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma.
Urology 2001;57(4):675-9.
2001: Jung K; Stephan C; Lein M; Brux B; Sinha P; Schnorr D; Loening S A
Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms--What has to be considered?
The Prostate 2001;46(4):307-10.
2001: Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening S A
Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):445-7.
2001: Jung M; Muche J M; Lukowsky A; Jung K; Loening S A
Dimethyl sulfoxide as additive in ready-to-use reaction mixtures for real-time polymerase chain reaction analysis with SYBR Green I dye.
Analytical biochemistry 2001;289(2):292-5.
2001: Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
European urology 2001;39(1):57-64.
2001: Yousef G M; Scorilas A; Jung K; Ashworth L K; Diamandis E P
Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer.
The Journal of biological chemistry 2001;276(1):53-61.
2000: Jung K; Lein M; Brux B; Sinha P; Schnorr D; Loening S A
Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2000;38(12):1271-5.
2000: Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening S A
Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Anticancer research 2000;20(6D):4997-5001.
2000: Stephan C; Jung K; Lein M; Schnorr D; Loening S A
Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
The Journal of urology 2000;164(5):1671-2.
2000: Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening S A
[Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients]
Der Urologe. Ausg. A 2000;39(6):554-6.
2000: Stephan C; Jung K; Lein M; Sinha P; Schnorr D; Loening S A
Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2000;9(11):1133-47.
2000: Magklara A; Scorilas A; Stephan C; Kristiansen G O; Hauptmann S; Jung K; Diamandis E P
Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue.
Urology 2000;56(3):527-32.
2000: Lein M; Stephan C; Jung K; Schnorr D; Loening S A
[Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis]
Der Urologe. Ausg. A 2000;39(4):313-23.
2000: Lein M; Koenig F; Misdraji J; McDougal W S; Jung K; Loening S A; Hasan T; Ortel B
Laser-induced hyperthermia in rat prostate cancer: role of site of tumor implantation.
Urology 2000;56(1):167-72.
2000: Jung M; Muche J M; Jung K; Loening S A
Methods in molecular biology: minor errors in primer citations with major consequences: how can we minimize these mistakes?
British journal of cancer 2000;82(9):1611-2; author reply 1612-3.
2000: Lein M; Jung K; Le D K; Hasan T; Ortel B; Borchert D; Winkelmann B; Schnorr D; Loenings S A
Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model.
The Prostate 2000;43(2):77-82.
2000: Stephan C; Jung K; Brux B; Lein M; Sinha P; Schnorr D; Loening S A
Elimination of serum complexed prostate-specific antigen after radical retropubic prostatectomy.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2000;38(4):309-11.
2000: Stephan C; Jung K; Brux B; Lein M; Sinha P; Schnorr D; Loening S A
ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation.
Urology 2000;55(4):560-3.
2000: Lein M; Jung K; Laube C; Hübner T; Winkelmann B; Stephan C; Hauptmann S; Rudolph B; Schnorr D; Loening S A
Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
International journal of cancer. Journal international du cancer 2000;85(6):801-4.
2000: Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening S A
Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Clinical chemistry 2000;46(1):55-62.
2000: Jung K; Brux B; Lein M; Rudolph B; Kristiansen G; Hauptmann S; Schnorr D; Loening S A; Sinha P
Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
Clinical chemistry 2000;46(1):47-54.
1999: Hampel G; Hosseini R; Jung K
Different effects of cyclosporine and tacrolimus on the activation of mesangial metalloproteinases and their inhibitors.
Transplantation proceedings 1999;31(7):2757-8.
1999: Filler G; Priem F; Vollmer I; Gellermann J; Jung K
Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate.
Pediatric nephrology (Berlin, Germany) 1999;13(6):501-5.
1999: Lein M; Jung K; Brux B; Knäbich A; Sinha P; Schnorr D; Loening S A
Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
The Journal of urology 1999;162(2):502-3.
1999: Lein M; Nowak L; Jung K; Laube C; Ulbricht N; Schnorr D; Loening S A
Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue.
Annals of the New York Academy of Sciences 1999;878():544-6.
1999: Lein M; Jung K; Nowak L; Schnorr D; Loening S A
Analytical aspects regarding the measurement of metalloproteinases.
Annals of the New York Academy of Sciences 1999;878():491-3.
1999: Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening S A
Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Urology 1999;53(6):1160-7; discussion 1167-8.
1999: Priem F; Althaus H; Birnbaum M; Sinha P; Conradt H S; Jung K
Beta-trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range.
Clinical chemistry 1999;45(4):567-8.
1999: Jung K; Brux B; Knäbich A; Lein M; Sinha P; Schnorr D; Loening S A
A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus alpha1-antichymotrypsin-prostate- specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia.
Clinical chemistry 1999;45(3):422-4.
1999: Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester G R; Jung K
Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
The Journal of rheumatology 1999;26(2):251-8.
1999: Friedrich B; Jung K; Lein M; Türk I; Rudolph B; Hampel G; Schnorr D; Loening S A
Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue.
European journal of cancer (Oxford, England : 1990) 1999;35(1):138-44.
1999: Petras T; Siems W; Henke W; Jung K; Olbricht C J; Gwinner W; Grune T
Metabolic rates of 4-hydroxynonenal in tubular and mesangial cells of the kidney.
Experimental nephrology 1999;7(1):59-62.
1999: Jung K; Zachow J; Lein M; Brux B; Sinha P; Lenk S; Schnorr D; Loening S A
Rapid detection of elevated prostate-specific antigen levels in blood: performance of various membrane strip tests compared.
Urology 1999;53(1):155-60.
1998: Keyszer G; Lambiri I; Keysser M; Keysser C; Nagel R; Burmester G R; Jung K
Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity.
Zeitschrift für Rheumatologie 1998;57(6):392-8.
1998: Jung K; Laube C; Lein M; Türk I; Lichtinghagen R; Rudolph B; Schnorr D; Loening S A
Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer.
International journal of cancer. Journal international du cancer 1998;78(3):392-3.
1998: Lein M; Koenig F; Jung K; McGovern F J; Skates S J; Schnorr D; Loening S A
The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men.
British journal of urology 1998;82(2):231-6.
1998: Lein M; Nowak L; Jung K; Koenig F; Schnorr D; Loening S A
[Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma]
Der Urologe. Ausg. A 1998;37(4):377-81.
1998: Jung K; Laube C; Lein M; Lichtinghagen R; Tschesche H; Schnorr D; Loening S A
Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood.
Clinical chemistry 1998;44(5):1060-2.
1998: Jung K; Meyer A; Lein M; Rudolph B; Schnorr D; Loening S A
Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
The Journal of urology 1998;159(5):1595-8.
1998: Henke W; Hagen T; Jung K; Loening S A
Periodate-oxidized ATP stimulates the permeability transition of rat liver mitochondria.
Biochimica et biophysica acta 1998;1363(3):209-16.
1998: Jung K; von Klinggräff P; Brux B; Sinha P; Schnorr D; Loening S A
Preanalytical determinants of total and free prostate-specific antigen and their ratio: blood collection and storage conditions.
Clinical chemistry 1998;44(3):685-8.
1998: Jung K; Lein M; Ulbrich N; Rudolph B; Henke W; Schnorr D; Loening S A
Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspects.
The Prostate 1998;34(2):130-6.
1998: Jung K; Friedrich B; Türk I; Roigas J; Lein M; Schnorr D; Loening S A
Cathepsins B, H, L and cysteine proteinase inhibitors in renal cell carcinoma: no evidence for dysregulated proteolytic balance.
Journal of cancer research and clinical oncology 1998;124(1):60-1.
1998: Lein M; Stephan C; Jung K; Schnorr D; Loening S
Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used?
Cancer investigation 1998;16(1):45-9.
1997: Meyer A; Jung K; Lein M; Rudolph B; Schnorr D; Loening S A
Factors influencing the ratio of free to total prostate-specific antigen in serum.
International journal of cancer. Journal international du cancer 1997;74(6):630-6.
1997: Haberland A; Henke W; Grune T; Siems W; Jung K; Schimke I
Differential response of oxygen radical metabolism in rat heart, liver and kidney to cyclosporine A treatment.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1997;46(11):452-4.
1997: Henke W; Herdel K; Jung K; Schnorr D; Loening S A
Betaine improves the PCR amplification of GC-rich DNA sequences.
Nucleic acids research 1997;25(19):3957-8.
1997: Jung K
Plasma but not serum should be used for determining tissue inhibitor of metalloproteinase in blood.
Alcoholism, clinical and experimental research 1997;21(6):1155-6.
1997: Lein M; Nowak L; Jung K; Koenig F; Lichtinghagen R; Schnorr D; Loening S A
Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood.
Clinical biochemistry 1997;30(6):491-6.
1997: Lein M; Brux B; Jung K; Henke W; Koenig F; Stephan C; Schnorr D; Loening S A
Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1997;35(8):591-5.
1997: Filler G; Witt I; Priem F; Ehrich J H; Jung K
Are cystatin C and beta 2-microglobulin better markers than serum creatinine for prediction of a normal glomerular filtration rate in pediatric subjects?
Clinical chemistry 1997;43(6 Pt 1):1077-8.
1997: Lein M; Jung K; Weiss S; Schnorr D; Loening S A
Soluble CD44 variants in the serum of patients with urological malignancies.
Oncology 1997;54(3):226-30.
1997: Jung K; Nowak L; Lein M; Priem F; Schnorr D; Loening S A
Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.
International journal of cancer. Journal international du cancer 1997;74(2):220-3.
1997: Stephan C; Lein M; Jung K; Schnorr D; Loening S A
Re: Editorial: can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?
The Journal of urology 1997;157(4):1371.
1997: Stephan C; Lein M; Jung K; Schnorr D; Loening S A
The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Cancer 1997;79(1):104-9.
1997: Henke W; Jung M; Jung K; Lein M; Schlechte H; Berndt C; Rudolph B; Schnorr D; Loening S A
Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood.
International journal of cancer. Journal international du cancer 1997;70(1):52-6.
1997: Jung K; Seidel B; Rudolph B; Lein M; Cronauer M V; Henke W; Hampel G; Schnorr D; Loening S A
Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells.
Free radical biology & medicine 1997;23(1):127-33.
1996: Jung K; Nowak L; Lein M; Henke W; Schnorr D; Loening S A
Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood.
Clinical chemistry 1996;42(12):2043-5.
1996: Jung K; Henke W; Lein M; Schnorr D; Loening S A
Polymerase chain reaction in the detection of micrometastases and circulating tumor cells.
Cancer 1996;78(11):2445-8.
1996: Lein M; Weiss S; Jung K; Schnorr D; Loening S
Soluble CD44 variants in serum of patients with prostate cancer and other urological malignancies.
The Prostate 1996;29(5):334-5.
1996: Jung K; Nowak L; Lein M; Henke W; Schnorr D; Loening S A
What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood?
Clinica chimica acta; international journal of clinical chemistry 1996;254(1):97-100.
1996: Henke W; Cetinsoy C; Jung K; Loening S
Non-hyperbolic calcium calibration curve of Fura-2: implications for the reliability of quantitative Ca2+ measurements.
Cell calcium 1996;20(3):287-92.
1996: Henke W; Jung M; Jung K; Lein M; Schlechte H; Berndt C; Rudolph B; Schnorr D; Loening S A
Detection of PSA mRNA in blood by RT-PCR does not exclusively indicate prostatic tumor cells.
Clinical chemistry 1996;42(9):1499-500.
1996: Stephan C; Jung K; Lein M; Schnorr D; Loening S A
The ratio of free to total prostate-specific antigen in serum is correlated to the prostate volume.
International journal of cancer. Journal international du cancer 1996;67(3):461-2.
1996: Jung K; Lein M; Henke W; Schnorr D; Loening S A
Isoforms of prostate-specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells?
The Prostate 1996;29(1):65-6.
1996: Jung K; Stephan C; Lein M; Henke W; Schnorr D; Brux B; Schürenkämper P; Loening S A
Analytical performance and clinical validity of two free prostate-specific antigen assays compared.
Clinical chemistry 1996;42(7):1026-33.
1996: Lein M; Jung K; Schnorr D; Henke W; Loening S A
Strip test for the quick detection of increased concentrations of prostate-specific antigen in blood.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1996;34(6):511-4.
1996: Jung K
Pyridoxal-5' -phosphate stimulation of aminotransferase activities in serum of hemodialysis patients and renal-transplant recipients.
Clinical nephrology 1996;45(6):416-7.
1996: Jung K; Lein M; Schnorr D; Brux B; Henke W; Loening S
Comparison between equimolar- and skewed-response assays of prostate specific antigen: is there an influence on the clinical significance when measuring total serum prostate specific antigen?
Annals of clinical biochemistry 1996;33 ( Pt 3)():209-14.
1996: Jung K; Lein M; Weiss S; Schnorr D; Henke W; Loening S
Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia.
European journal of cancer (Oxford, England : 1990) 1996;32A(4):627-30.
1996: Jung K; Henke W
Developmental changes of antioxidant enzymes in kidney and liver from rats.
Free radical biology & medicine 1996;20(4):613-7.
1995: Lein M; Jung K; Schnorr D; Henke W; Brux B; Loening S A
Rapid screening of PSA: evaluation of an immunochemical membrane strip test.
Clinical chemistry 1995;41(10):1545-7.
1995: Jung K; Scheifler A; Schulze B D; Scholz M
Lower serum high-density lipoprotein-cholesterol concentration in patients undergoing maintenance hemodialysis with acetate than with bicarbonate.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1995;25(4):584-8.
1995: Henke W; Jung K; Polster F
Effects of preservation solutions on cortical and medullary mitochondria of rat kidney.
Cellular and molecular biology (Noisy-le-Grand, France) 1995;41(2):319-26.
1995: Jung K; Jung M
Cystatin C: a promising marker of glomerular filtration rate to replace creatinine.
Nephron 1995;70(3):370-1.
1994: Fels L M; Bundschuh I; Gwinner W; Jung K; Pergande M; Graubaum H J; Price R G; Taylor S A; De Broe M E; Nuyts G D
Early urinary markers of target nephron segments as studied in cadmium toxicity.
Kidney international. Supplement 1994;47():S81-8.
1994: Jung K
Urinary enzymes and low molecular weight proteins as markers of tubular dysfunction.
Kidney international. Supplement 1994;47():S29-33.
1994: Fels L M; Herbort C; Pergande M; Jung K; Hotter G; Roselló J; Gelpi E; Mutti A; De Broe M; Stolte H
Nephron target sites in chronic exposure to lead.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1994;9(12):1740-6.
1994: Pergande M; Jung K; Precht S; Fels L M; Herbort C; Stolte H
Changed excretion of urinary proteins and enzymes by chronic exposure to lead.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1994;9(6):613-8.
1993: Jung K; Pergande M; Priem F; Becker S; Klotzek S
Rapid screening of low molecular mass proteinuria: evaluation of the first immunochemical test strip for the detection of alpha 1-microglobulin in urine.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1993;31(10):683-7.
1993: Pergande M; Jung K
Sandwich enzyme immunoassay of cystatin C in serum with commercially available antibodies.
Clinical chemistry 1993;39(9):1885-90.
1993: Jung K; Priem F
What are the criteria to introduce new methods for determination of urinary N-acetyl-beta-D-glucosaminidase activity?
Annals of clinical biochemistry 1993;30 ( Pt 5)():501-4.
1993: Henke W; Jung K
Comparison of the effects of the immunosuppressive agents FK 506 and cyclosporin A on rat kidney mitochondria.
Biochemical pharmacology 1993;46(5):829-32.
1993: Jung K; Kirschner P; Wille A; Brien G
Excretion of urinary enzymes after extracorporeal shock wave lithotripsy: a critical reevaluation.
The Journal of urology 1993;149(6):1409-13.
1993: Jung K; Pergande M; Graubaum H J; Fels L M; Endl U; Stolte H
Urinary proteins and enzymes as early indicators of renal dysfunction in chronic exposure to cadmium.
Clinical chemistry 1993;39(5):757-65.
1993: Bundschuh I; Herbort C; Fels L M; Jung K; Graubaum H J; Stolte H
Renal fibronectin excretion as a marker for renal environmental toxins.
Contributions to nephrology 1993;101():177-84.
1993: Jung K; Kühler S; Klotzek S; Becker S; Henke W
Effect of storage temperature on the activity of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione S-transferase in rat liver and kidney homogenates.
Enzyme & protein 1993;47(3):149-55.
1992: Müller K; Siems W G; Grune T; David H; Henke W; Jung K
Adaptational increase of liver glutathione content during long-term application of cyclosporine A may attenuate toxic side effects.
Cellular and molecular biology (Noisy-le-Grand, France) 1992;38(7):729-38.
1992: Jung K; Henke W; Schulze B D; Sydow K; Precht K; Klotzek S
Practical approach for determining glomerular filtration rate by single-injection inulin clearance.
Clinical chemistry 1992;38(3):403-7.
1992: Jung K; Pergande M; Schreiber G; Thierfelder W
Reference intervals for alpha 1-microglobulin in urine.
Clinica chimica acta; international journal of clinical chemistry 1992;206(3):245-7.
1992: Henke W; Nickel E; Jung K
Cyclosporine A inhibits ATP net uptake of rat kidney mitochondria.
Biochemical pharmacology 1992;43(5):1021-4.
1992: Jung K; Pergande M
Sex- and age-dependent reference values of alpha-1-microglobulin in urine.
Nephron 1992;62(4):474-5.
1991: Jung K; Priem F
A practical new assay for determining N-acetyl-beta-D-glucosaminidase activity in urine.
Clinica chimica acta; international journal of clinical chemistry 1991;203(2-3):405-7.
1991: Jung K
Enzyme activities in urine: how should we express their excretion? A critical literature review.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1991;29(11):725-9.
1991: Henke W; Jung K
Ischemia decreases the content of the adenine nucleotide translocator in mitochondria of rat kidney.
Biochimica et biophysica acta 1991;1056(1):71-5.
1991: Jung K; Klotzek S
[Determination of kallikrein in gel-filtered urine using the chromogenic substrate D-valyl-L-leucyl-L-arginyl-4-nitroanilide]
Zeitschrift für medizinische Laboratoriumsdiagnostik 1991;32(2):116-7.
1991: Jung K; Klotzek S; Schulze B D
[Evaluation of methods for the analysis of low insulin concentrations in serum]
Zeitschrift für medizinische Laboratoriumsdiagnostik 1991;32(1):23-9.
1991: Jung K; Priem F; Stolte H; Graubaum H J; May G
[Excretion of beta-N-acetylglucosaminidase in urine of patients with kidney transplants and workers exposed to cadmium]
Wiener klinische Wochenschrift. Supplementum 1991;189():56-9.
1991: Jung K; Priem F; Klein G
[A new kinetic method for measuring beta-N-acetylglucosaminidase activity in urine]
Wiener klinische Wochenschrift. Supplementum 1991;189():39-44.
1991: Jung K; Priem F; Klotzek S; Becker S; Henke W
Methods compared for determining activity of N-acetyl-beta-D-glucosaminidase in urine without pretreatment of sample: different sensitivity and species effect.
Enzyme 1991;45(4):215-21.
1991: Jung K; Priem F; Henke W; Klotzek S; Becker S
Evaluation of methods for determining N-acetyl-beta-D-glucosaminidase in urine of rats without purification of urine samples.
Journal of experimental animal science 1991;34(4):147-52.
1991: Henke W; Ziegler M; Dubiel W; Jung K
Mechanisms accounting for changes of adenine nucleotide content in mitochondria at ischemia.
Advances in experimental medicine and biology 1991;309A():309-12.
1991: Jung K; Henke W; Schulze B D; Sydow K; Precht K; Klotzek S
Single-injection inulin clearance using only one blood sample as a suitable procedure to measure glomerular filtration rate.
Nephron 1991;59(4):694-5.
1991: Jung K; Becker S
Multiple forms of N-acetyl-beta-D-glucosaminidase of human urine: isolation, properties and the development of a practical approach of differentiation.
Biomedica biochimica acta 1991;50(7):861-7.
1990: Porstmann T; Schmechta H; Hentschel C; Doepel H; Pas P; Becker J; Pergande M; Jung K; Nugel E
Development of an immunoenzymometric assay for alpha 1-microglobulin and measurement of its serum concentration in normal and HIV-infected persons.
Journal of clinical chemistry and clinical biochemistry. Zeitschrift für klinische Chemie und klinische Biochemie 1990;28(10):669-75.

Sign-in to see more